A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2749 participants.
Also called NCT05803421
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,749 participants
- Sponsor
- Registry
-
NCT05803421
-
- Other papers using this trial's data
- Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Austria, Brazil, Czechia, Germany, Greece, India, Italy, Mexico, Puerto Rico, Romania, Slovakia, South Korea, Spain, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT05803421. Randomized; no masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2026-03-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- Acronym
- ACHIEVE-4
- Condition
- Type 2 Diabetes
- Condition
- Obesity
- Condition
- Overweight or Obesity
- Condition
- Overweight
- Condition
- Cardiovascular Diseases
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Orforglipron
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05803421- Content hash
2add84c094d45621f7d560cdb1e09d16d7563e6951676684b140b2b693c7205d